beta-blockade, atrial natriuretic peptide and exercise

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Pharmacology

Background:

• Beta-adrenoceptor blocking therapy outcomes may be influenced by atrial natriuretic peptide (ANP) and vasopressin (VP) release.
• Understanding the effects of different beta-blockers on these hormones is crucial for optimizing therapeutic strategies.

Purpose of the Study:

• To investigate the impact of atenolol, propranolol, and pindolol on plasma ANP and VP levels during exercise in healthy volunteers.
• To compare the beta-adrenoceptor antagonism and agonism profiles of these beta-blockers in relation to hormonal responses.

Main Methods:

• A randomized, double-blind, placebo-controlled crossover study involving 15 healthy volunteers.
• Administration of atenolol, propranolol, or pindolol prior to a 30-minute bicycle exercise test.
• Measurement of plasma ANP, VP, adrenaline, and noradrenaline concentrations to assess hormonal release and sympathoadrenal activation.

Main Results:

• All beta-blockers and placebo similarly increased plasma ANP levels during exercise.
• Pindolol administration enhanced the decline of plasma ANP post-exercise and increased mean plasma VP levels.
• Differences in beta 1- and beta 2-adrenoceptor occupancy were observed among the agents.

Conclusions:

• Beta 1- and beta 2-antagonism by pindolol, atenolol, and propranolol do not significantly alter plasma ANP and VP responses to physical exercise.
• Pindolol's beta-agonist activity may subtly influence these hormonal responses.
• Hormonal changes during exercise are minimally affected by common beta-blocker therapies.